GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Cyclically Adjusted PB Ratio

Akari Therapeutics (FRA:CLA) Cyclically Adjusted PB Ratio : 0.08 (As of Jun. 23, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-23), Akari Therapeutics's current share price is €2.82. Akari Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €36.54. Akari Therapeutics's Cyclically Adjusted PB Ratio for today is 0.08.

The historical rank and industry rank for Akari Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:CLA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.46
Current: 0.09

During the past years, Akari Therapeutics's highest Cyclically Adjusted PB Ratio was 0.46. The lowest was 0.00. And the median was 0.00.

FRA:CLA's Cyclically Adjusted PB Ratio is ranked better than
89.36% of 658 companies
in the Biotechnology industry
Industry Median: 1.66 vs FRA:CLA: 0.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Akari Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €-0.409. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €36.54 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Akari Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Akari Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Cyclically Adjusted PB Ratio Chart

Akari Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.15

Akari Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.43 0.15 0.05

Competitive Comparison of Akari Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Akari Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akari Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Cyclically Adjusted PB Ratio falls into.



Akari Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Akari Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.82/36.54
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akari Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Akari Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.409/131.7762*131.7762
=-0.409

Current CPI (Mar. 2024) = 131.7762.

Akari Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201312 211.039 98.326 282.834
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 64.809 99.070 86.205
201503 86.197 99.621 114.019
201506 31.165 100.684 40.789
201509 62.539 100.392 82.090
201512 75.953 99.792 100.296
201603 70.695 100.470 92.723
201606 61.340 101.688 79.490
201609 62.099 101.861 80.337
201612 54.904 101.863 71.027
201703 35.561 102.862 45.557
201706 34.539 103.349 44.039
201709 18.582 104.136 23.514
201712 19.001 104.011 24.073
201803 17.355 105.290 21.721
201806 9.681 106.317 11.999
201809 6.835 106.507 8.457
201812 3.460 105.998 4.301
201903 1.362 107.251 1.673
201906 -1.471 108.070 -1.794
201909 2.809 108.329 3.417
201912 0.006 108.420 0.007
202003 1.144 108.902 1.384
202006 1.751 108.767 2.121
202009 2.435 109.815 2.922
202012 4.010 109.897 4.808
202103 1.719 111.754 2.027
202106 0.665 114.631 0.764
202109 4.059 115.734 4.622
202112 2.066 117.630 2.314
202203 4.263 121.301 4.631
202206 2.654 125.017 2.797
202212 0.454 125.222 0.478
202303 0.000 127.348 0.000
202306 0.507 128.729 0.519
202312 -0.032 129.419 -0.033
202403 -0.409 131.776 -0.409

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Akari Therapeutics  (FRA:CLA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Akari Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Akari Therapeutics (FRA:CLA) Business Description

Traded in Other Exchanges
Address
75/76 Wimpole Street, London, GBR, W1G 9RT
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.